AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) has scheduled an investor webinar briefing for August 12, 2026, to provide shareholders and prospective investors with an update on its recent financial performance. The event serves as a direct engagement platform for the company’s leadership team to discuss operational outcomes and address investor inquiries regarding the therapeutic acute wound care firm’s trajectory.

The webinar is set to begin at 4:00 p.m. Pacific Time on August 12, 2026, which corresponds to 9:00 a.m. Australian Eastern Standard Time on August 13, 2026. Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, will lead the presentation. The session will focus on the financial and business results reported during AVITA Medical’s recent second-quarter 2026 earnings webcast, ensuring that investors have access to detailed commentary beyond the initial earnings release.

Event Details and Registration

Participants are invited to register for the virtual event via the company’s designated Zoom link. Questions from attendees can be submitted through the registration page prior to the live session. A replay of the webinar will be made available on AVITA Medical’s investor relations website following the conclusion of the live broadcast, allowing those unable to attend in real time to review the material.

Business Overview

AVITA Medical operates as a leading therapeutic acute wound care company, delivering solutions designed to optimize wound healing and accelerate patient recovery. Its flagship technology, RECELL, is approved by the U.S. Food and Drug Administration (FDA) for the treatment of thermal burn and trauma wounds. RECELL utilizes a patient’s own skin cells to create Spray-On Skin, offering an innovative point-of-care solution.

In the United States, AVITA Medical holds exclusive rights to market, sell, and distribute Cohealyx, a collagen-based dermal matrix, as well as PermeaDerm, a biosynthetic wound matrix. Internationally, RECELL and RECELL GO hold CE marks in Europe, TGA certification in Australia, Medsafe listing in New Zealand, and PMDA approval in Japan, reflecting the company’s broad regulatory footprint across key global markets.

AVITA Medical Inc., a therapeutic acute wound care company listed on NASDAQ (RCEL) and ASX (AVH), announced its participation in the Canaccord Genuity 46th Annual Growth Conference. The event will take place in Boston from August 11–13, 2026. This appearance provides investors with an opportunity to engage directly with management regarding the company’s strategic direction and clinical portfolio, which includes FDA-approved RECELL technology for thermal burn and trauma wounds.

Conference Details

President and CEO Cary Vance will deliver a presentation on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. The session aims to update stakeholders on AVITA Medical’s progress in delivering transformative solutions for acute wound care. Investors attending the conference may request one-on-one meetings with AVITA Medical representatives through their Canaccord Genuity sales representative.

Webcast Access

For investors unable to attend in person, AVITA Medical will provide a live webcast of the presentation. A replay of the session will also be available under the Investor Relations Events & Presentations section of the company’s website at https://ir.avitamedical.com/events-and-presentations .

About AVITA Medical

AVITA Medical specializes in technologies designed to optimize wound healing and accelerate patient recovery. Its flagship product, RECELL, is approved by the FDA for treating thermal burn and trauma wounds by harnessing the healing properties of a patient’s own skin to create Spray-On Skin. The company holds exclusive rights in the U.S. to market Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Internationally, RECELL is CE-marked in Europe, TGA-certified in Australia, listed with Medsafe in New Zealand, and PMDA-approved in Japan.

Contact Information

Investor inquiries should be directed to Ben Atkins at +1-805 341 1571 or investor@avitamedical.com . Media inquiries can be sent to media@avitamedical.com . The release was authorized by the Chief Financial Officer of AVITA Medical Inc.